The platform's lead drug candidate, ResectAssist™-FOLFIRINOX, focuses on LAPC, delivering high-dose FOLFIRINOX chemotherapy (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) directly into ...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol ...

The successful enrollment of all three cohorts in the CENDIFOX trial is another significant milestone, bringing us closer to validating certepetide’s potential as a transformative treatment for ...